Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced the appointment of R. LaDuane ...
SUNRISE, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, ...
SUNRISE, Fla., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, ...
• TRB-ONC1 granted U.S. Orphan Drug Designation by the FDA for the treatment of glioblastoma (GBM) SUNRISE, Fla., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated, clinical-stage ...
WESTON, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated, clinical-stage biopharmaceutical company focused on developing inhaled medicines, today announced the company dosed the ...
Transpire Bio has tapped Recipharm to support the development of its inhaled respiratory disease drug candidates. The agreement positions Transpire to tap into Recipharm’s experience of developing and ...
NEW YORK--(BUSINESS WIRE)--CI&T (NYSE: CINT), a global digital specialist, announces today, as a complement to the market announcement of August 16, 2022, the completion of the acquisition of ...
Brazilian IT consultancy firm CI&T kept up its buying spree with the acquisition of Australian rival Transpire Technology, gaining access to several deep-pocketed clients in the South Pacific country.
SUNRISE, Fla., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results